HLA-DRA
HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
Overview
An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Nivolumab, Pembrolizumab and Atezolizumab.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
- 1 · What it is
HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
- 2 · What goes wrong in cancer
An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule.
- 3 · How drugs use it
No product in this corpus aims at HLA-DRA yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:4947 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P01903 (protein name, function text, keywords and locations (REST API)); CIViC gene HLA-DRA (1 evidence items, 0 assertions, 1 variants; diseases: Skin Melanoma (GraphQL API, CC0))
Biology
An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumour microenvironment, presents antigenic peptides that are primarily generated in tumour-resident APCs likely via phagocytosis of apoptotic tumour cells or macropinocytosis of secreted tumour proteins. Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance. Location: Cell membrane; Endoplasmic reticulum membrane; Early endosome membrane; Late endosome membrane (UniProt). Locus 6p21.32 (HGNC).
- Melanoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"HLA-DRA" OR ABSTRACT:"HLA-DRA" OR TITLE:"major histocompatibility complex, class II, DR alpha" OR ABSTRACT:"major histocompatibility complex, class II, DR alpha" OR TITLE:"HLA class II histocompatibility antigen, DR alpha chain" OR ABSTRACT:"HLA class II histocompatibility antigen, DR alpha chain" OR TITLE:"HLA-DRA1" OR ABSTRACT:"HLA-DRA1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLA-DRA, not a curated reading list.